国信证券晨会纪要-20251121
Guoxin Securities·2025-11-21 02:18

Core Insights - The report highlights strong performance in the textile and apparel industry, particularly for Amer Sports, which reported a 26% year-on-year revenue increase for the first three quarters of 2025, reaching $4.465 billion, and a 153% increase in adjusted net profit to $369 million [5][6] - The report also notes the positive outlook for the media and internet sector, with Marble 3D's world model public beta launch and a focus on AI applications [7][8] - In the pharmaceutical sector, Eli Lilly's revenue surged by 52% in Q3 2025, driven by GLP-1 drugs, with Tirzepatide exceeding $10 billion in quarterly revenue [10][11] Textile and Apparel Industry - Amer Sports' Q3 2025 performance showed a 30% revenue increase, with adjusted net profit rising by 161% to $185 million [5][6] - The management has raised its full-year guidance for revenue growth to 23-24%, with an expected EPS of $0.88-$0.92 [6] - Key growth drivers include the Salomon brand, direct-to-consumer (DTC) channels, and strong performance in the Greater China and Asia-Pacific regions [6] Media and Internet Sector - The media industry experienced a decline of 2.31%, underperforming compared to the broader market indices [7] - Marble 3D's public beta launch is expected to enhance opportunities in the sector, with significant advancements in AI technology [8] - The report emphasizes the potential for growth in gaming and IP trends, recommending companies like Giant Network and Kuaishou [8] Pharmaceutical Industry - Eli Lilly's Q3 2025 revenue growth was significantly driven by its GLP-1 drug portfolio, with a notable increase in market coverage due to pricing agreements with the U.S. government [10][11] - Novo Nordisk faced challenges in the competitive landscape for weight loss drugs, leading to multiple downward revisions of its performance guidance [11][12] - The report indicates that 11 out of 16 multinational pharmaceutical companies raised their revenue and profit forecasts for the year, reflecting better-than-expected sales from new products [12]